Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation (LICE OUT)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Topaz Pharmaceuticals Inc
ClinicalTrials.gov Identifier:
NCT01066585
First received: February 8, 2010
Last updated: April 4, 2012
Last verified: April 2012

February 8, 2010
April 4, 2012
March 2010
June 2010   (final data collection date for primary outcome measure)
Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) [ Time Frame: Day 2 up to Day 15 post-application ] [ Designated as safety issue: No ]
Treatment success defined as absence of live lice, was assessed in index participants, defined as the youngest person within each household who had at least 3 live lice present at Screening (Day 1). Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation.
The proportion within each treatment group of index subjects who are lice free [ Time Frame: 15 Days ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01066585 on ClinicalTrials.gov Archive Site
  • Percentage of All Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) [ Time Frame: Day 2 up to Day 15 post-application ] [ Designated as safety issue: No ]
    Treatment success, defined as absence of live lice, was assessed in all subjects. Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation.
  • Number of Participants Reporting Treatment-Emergent Adverse Events Post-treatment With Either Ivermectin or Placebo (Vehicle Control) [ Time Frame: Day 1 up to Day 15 post-application. ] [ Designated as safety issue: No ]

    Severity of the adverse events were defined and classified as follows:

    'Mild' - Awareness of signs or symptoms, but easily tolerated; 'Moderate' - Discomfort to a degree that adverse event/adverse drug reaction causes interference with normal daily life activities and/or requires medication; 'Severe' - Incapacity with regard to work or usual daily life activities. Requires medical attention/intervention.

  • Summary of the Reported Skin/Scalp Irritation Before Treatment and Post-treatment With Either Ivermectin or Placebo (Vehicle Control) [ Time Frame: Day 1 up to Day 15 post-application ] [ Designated as safety issue: No ]

    Severe skin/scalp irritations were defined as follows:

    Severe Pruritus - Nearly constant, frequent scratching, very bothersome; Severe Erythema - large areas of the scalp are red; Severe Excoriation - Widespread breaking of the skin involving most of the scalp; Severe Pyoderma - Lesions with crusting or other evidence of infection, involving most of the scalp.

  • The proportion within each treatment group of all subjects who are lice free [ Time Frame: 15 days ] [ Designated as safety issue: No ]
  • The assessments of reported adverse events [ Time Frame: 15 days ] [ Designated as safety issue: No ]
  • Observed skin/scalp reactions and ocular irritation assessments [ Time Frame: 15 days ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation
A Double-Blind Randomized Study to Compare the Efficacy, Safety and Local Tolerability of a 0.5% Ivermectin Cream Compared to a Topical Vehicle Control in Subjects With Pediculus Humanus Capitis Infestation

The purpose of this study is to determine if 0.5% Ivermectin Cream is a safe and effective treatment for head lice infestations.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Head Lice
  • Drug: Ivermectin Cream
    Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1
  • Drug: vehicle control
    Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
  • Experimental: 0.5% Ivermectin Cream
    Intervention: Drug: Ivermectin Cream
  • Placebo Comparator: Vehicle control
    Intervention: Drug: vehicle control
Pariser DM, Meinking TL, Bell M, Ryan WG. Topical 0.5% ivermectin lotion for treatment of head lice. N Engl J Med. 2012 Nov;367(18):1687-93. doi: 10.1056/NEJMoa1200107.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
410
July 2010
June 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Index subjects must have an active head lice infestation defined as: At least 3 live lice (adults and/or nymphs) present on the scalp and/or hair, as determined by a trained evaluator. The index subject must be the youngest family member presenting with at least 3 live lice. After the index subject has been identified, additional infested household members (see b below) will be enrolled.
  • Household subjects must have an active head lice infestation defined as: At least 1 live louse (adult and/or nymph) present on the scalp and/or hair, as determined by a trained evaluator (with the exception of the male head of household who may self-assess as being lice free).
  • Subject is male or female.
  • Subject is at least 6 months of age at time of enrollment.
  • Subject is in good general health based on medical history.
  • Each subject must have an appropriately signed Informed Consent agreement. A caregiver must sign an Informed Consent agreement for children not old enough to do so. Children of a specified age will be administered a child's assent form.
  • The caregiver of a subject must be willing to allow all household members to be screened for head lice. If other household members are found to have an active head lice infestation, according to the criteria b (above), they must be willing and able to participate in the study. No more than one working male per household may be excluded from evaluation if he is assessed as being lice free by himself or the caregiver and cannot come in due to his work schedule. If this individual may have lice, he must come to the test facility; otherwise the entire household will be excluded from study participation.
  • Subject and/or their caregiver must be physically able and willing to apply the test article.
  • Subject agrees not to use any other form of lice treatments (commercial, community-anecdotal, or mechanical/manual) while participating in the study.
  • Following application and rinsing of the test article, subject agrees not to shampoo, wash, or rinse their hair or scalp until the 24-hour post-treatment evaluation has been completed.
  • Subject agrees to not cut or chemically treat their hair while participating in the study.
  • Subject agrees to follow all study instructions.
  • Female subjects of childbearing potential (including a female caregiver even if she is not being treated) must be willing to have a urine pregnancy test.
  • In the event of a subject judged to be incapable of self-treating, the household must have a caregiver willing to apply the treatment at home.

Exclusion Criteria:

  • History of irritation or sensitivity to ivermectin or the cream components, pediculicides or hair care products.
  • Presentation at the treatment site with visible skin/scalp condition(s) that are not attributable to head lice infestation, such as an erythema score that is >2, blisters, vesicles which, in the opinion of the investigative personnel or sponsor, will interfere with safety and/or efficacy evaluations.
  • Presentation at the treatment site with eczema or atopic dermatitis.
  • Treatment for head lice (Over the counter [OTC], home remedy and/or Prescription) in the last 7 days.
  • Any condition or illness that, in the opinion of the investigator, may compromise the objective of the protocol.
  • Is receiving any other treatment which, in the opinion of the investigator or study monitor, may interfere with the study results.
  • Females (including caregivers who come in contact with the investigational product) who are pregnant, nursing or planning a pregnancy. (NOTE: female caregivers and all enrolled females of childbearing potential must have a negative urine pregnancy test prior to treatment). If a household has a pregnant female who has an active case of lice, the entire household is excluded from participation. If this pregnant household member does not have an active infestation, this individual must NOT be the caregiver (one who provides treatment to other household members).
  • Is of child-bearing potential and unwilling to use an adequate method of contraception for the duration of the study. Adequate methods of contraception include: abstinence, vasectomized partner, oral birth control pills, birth control injections or patches, Intra uterine devices, condoms with a spermicidal jelly or a diaphragm with spermicidal jelly, surgical sterilization.
  • Participation in a previous investigational drug study within the past 30 days.
  • Prior participation in any ivermectin trials.
  • Does not understand the requirements for study participation and/or may likely exhibit poor compliance, in the opinion of the investigator.
  • Does not have a known household affiliation with their household members (i.e., do not stay in one household consistently, sleeping at one place several nights and then at another place or location). Household is defined as living in a shared area or space (for example the same house or apartment unit).
Both
6 Months and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01066585
TOP011
No
Topaz Pharmaceuticals Inc
Topaz Pharmaceuticals Inc
Not Provided
Study Chair: Medical Director Sanofi Topaz
Topaz Pharmaceuticals Inc
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP